Phathom Pharmaceuticals opened lower at $6.21, compared with its previous close of $6.28. In the last trading session, the stock traded between $6.10 and $6.38. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Phathom Pharmaceuticals is now worth
$ 28.37
Resulting in a loss of
$ 71.63 (71.63%)
Note: Past profits do not guarantee future returns.
Rating from 6 Analysts
Today's Change
$-0.04 (-0.62%)
Day High
$6.38
Day Low
$6.10
Day Open
$6.21
Prev Close
$6.28
Volume
8,69,589
1W Return
9.97%
1M Return
-12.41%
3M Return
-26.36%
6M Return
-48.93%
1Y Return
-56.54%
Market Cap ($ Mn)
507
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-84.71%
EPS (TTM)
$-0.17
1 Week
9.97%
1 Month
-12.41%
3 Months
-26.36%
6 Months
-48.93%
9 Months
-48.97%
Phathom Pharmaceuticals initiates Phase 3 study for VOQUEZNA in NERD
Phathom Pharmaceuticals initiates registrational Phase 3 study pHalcon-NERD-302 for VOQUEZNA. Study targets as-needed treatment of Non-Erosive Reflux Disease (NERD). Topline results expected in first quarter of 2028. Aim is to support label expansion where PPIs are not approved for PRN use in U.S.
1mo agoSBS Law investigates Phathom Pharmaceuticals over revenue forecast cut
Schall, Brown & Schwartz LLP investigates Phathom Pharmaceuticals for securities violations. Probe triggered by July 30, 2026 full-year revenue forecast cut. Company had reaffirmed prior guidance as recently as April 2026. Shares fell sharply following the revised outlook announcement.
1mo agoPortnoy Law investigates Phathom Pharmaceuticals over revenue miss
Portnoy Law Firm investigates Phathom Pharmaceuticals, Inc. for securities fraud after the company cut its 2026 revenue guidance by up to $20 million. The probe contrasts management's claims of a robust sales force with the subsequent downgrade in financial expectations.
3mo agoLevi & Korsinsky probes Phathom after revenue guidance cut
Phathom Pharmaceuticals faces a securities investigation by Levi & Korsinsky after cutting FY26 revenue guidance to $310-$325 million, missing consensus estimates of $332-$334 million. The probe examines potentially misleading statements regarding the commercial ramp of its key product, VOQUEZNA.
3mo agoHC Wainwright Reiterates Buy on Phathom Pharmaceuticals, Keeps $26 Target
HC Wainwright & Co. analyst Matthew Caufield reiterates a Buy rating on Phathom Pharmaceuticals with a $26 price target. The move reflects continued confidence in the biotech firm's outlook, providing investors with a stable valuation benchmark amidst market volatility.
3mo agoPhathom Pharmaceuticals Q2 Results: Sales surge 88% YoY
Phathom Pharmaceuticals delivered a strong second quarter with adjusted EPS of $0.00, beating the $(0.25) estimate. Sales reached $74.300 million, up 88.09% YoY and above the $72.789 million forecast. The results reflect significant improvement in both profitability and revenue generation compared to the prior year.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Phathom Pharmaceuticals is now worth
$ 28.37
Resulting in a loss of
$ 71.63 (71.63%)
Note: Past profits do not guarantee future returns.
